Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026GlobeNewsWire • 10/24/26
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026GlobeNewsWire • 10/23/26
Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing IntervalSeeking Alpha • 10/07/26
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and BudoprutugGlobeNewsWire • 10/02/26
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA NephropathyGlobeNewsWire • 09/03/26
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate VolatilitySeeking Alpha • 07/23/26
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026GlobeNewsWire • 06/11/26
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued DevelopmentGlobeNewsWire • 06/05/26
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026GlobeNewsWire • 05/26/26
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 CongressGlobeNewsWire • 05/14/26
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/07/26
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data ReadoutsGlobeNewsWire • 05/05/26
Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions UnderwaySeeking Alpha • 04/16/26
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026GlobeNewsWire • 04/08/26
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous NephropathyGlobeNewsWire • 04/07/26
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/05/26